Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis

BACKGROUND: Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness and safety in other populations, including those with Child-Turcotte-Pugh (CTP) class B cirrhosis, is unclear. METHODS: For...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Anand V., Tevethia, Harshvardhan, Kumar, Karan, Premkumar, Madhumita, Muttaiah, Mark D., Hiraoka, Atsushi, Hatanaka, Takeshi, Tada, Toshifumi, Kumada, Takashi, Kakizaki, Satoru, Vogel, Arndt, Finn, Richard S., Rao, Padaki Nagaraja, Pillai, Anjana, Reddy, Duvvur Nageshwar, Singal, Amit G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480543/
https://www.ncbi.nlm.nih.gov/pubmed/37680945
http://dx.doi.org/10.1016/j.eclinm.2023.102179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480543/
https://www.ncbi.nlm.nih.gov/pubmed/37680945
http://dx.doi.org/10.1016/j.eclinm.2023.102179

Ejemplares similares